BioSpace News Archive

Drug Development

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced alignment with the FDA’s recommendation for a Phase 3 trial in the TRANQUILITY program.

November 14, 2023
·
17 min read
Business

Evofem Biosciences Announces Financial Results for the Third Quarter of 2023

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023.

November 14, 2023
·
8 min read
Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)

Alvotech and JAMP Pharma Group announced that Health Canada has granted JAMP Pharma marketing authorization for AVT04, a biosimilar to Stelara® developed by Alvotech.

November 14, 2023
·
10 min read
Business

CASI Pharmaceuticals Announces Third Quarter 2023 Business and Financial Updates

CASI Pharmaceuticals, Inc. reported business and financial results for the third quarter ended September 30, 2023.

November 14, 2023
·
9 min read
Drug Development

Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases

Transposon Therapeutics announced its abstract of interim results from its Phase 2 study of TPN-101 for the treatment of progressive supranuclear palsy has been accepted for poster presentation at the hybrid AD/PD™ 2024: 18th International Conference on Alzheimer’s and Parkinson’s Diseases.

November 14, 2023
·
5 min read
Business

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced certain financial and operational results for the third quarter ended September 30, 2023.

November 14, 2023
·
14 min read
Business

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Silence Therapeutics plc reported its financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

November 14, 2023
·
9 min read
Lone Star Bio

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that data spanning its dermatologic portfolio of gene expression profile tests was recently presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago.

November 14, 2023
·
11 min read
BioMidwest

NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference

NeoGenomics, Inc., a leading oncology testing services company, announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New York City.

November 14, 2023
·
2 min read
BioMidwest

Ludwig Enterprises Announces Effectiveness of Form S-1 Registration Application, Becomes an SEC Reporting Company

Ludwig Enterprises, Inc. announced that the U.S. Securities and Exchange Commission has declared the Company’s Registration Statement on Form S-1 effective as of November 8, 2023.

November 14, 2023
·
3 min read